Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Salman Tahir Shafi

doi:10.53778/pjkd40353

Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients

Authors

Salman Tahir Shafi Sharif Medical and Dental College, Lahore

DOI:

https://doi.org/10.53778/pjkd40353

Keywords:

Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, Tocilizumab

Abstract

Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.

Downloads

Published

2021-01-31

How to Cite

Shafi, S. T. (2021). Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353